Generic copies of the original formulation of the painkiller OxyContin will not receive regulatory approval, the FDA announced Tuesday. The version was recalled by the agency due to safety concerns after Purdue Pharma's patent expired, blocking other drugmakers from producing generic forms. The FDA also allowed new labeling for the reformulated version of OxyContin, which will point out that the tablets are harder to crush, a property that makes abuse more difficult.

Related Summaries